

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

Hu CD45 BUV395 HI30 100Tst

RRID:AB_2869519

Type: Antibody

Proper Citation

BD Biosciences Cat# 563792, RRID:AB_2869519

Antibody Information

URL: http://antibodyregistry.org/AB_2869519

Proper Citation: BD Biosciences Cat# 563792, RRID:AB_2869519

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Hu CD45 BUV395 HI30 100Tst

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: HI30

Antibody ID: AB_2869519

Vendor: BD Biosciences

Catalog Number: 563792

Record Creation Time: 20250819T233604+0000

Record Last Update: 20250820T055100+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD45 BUV395 HI30 100Tst.

No alerts have been found for Hu CD45 BUV395 HI30 100Tst.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Deng J, et al. (2026) Macrophage MR1 antigen presentation promotes MAIT cell immunity and lung microbiota modulation. *Science (New York, N.Y.)*, 391(6782), eadr6322.

Fernandes P, et al. (2026) Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice. *Cell host & microbe*, 34(1), 116.

Hasanov M, et al. (2025) Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. *Oncoimmunology*, 14(1), 2546402.

Cooney JP, et al. (2025) Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo. *Cell*, 188(18), 4896.

Krapi? M, et al. (2025) NK cell-derived IFN? mobilizes free fatty acids from adipose tissue to promote early B cell activation during viral infection. *Nature metabolism*, 7(5), 985.

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. *Cell stem cell*, 32(7), 1087.

Garcia GL, et al. (2025) Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation. *Cancer discovery*, 15(6), 1203.

Yang BH, et al. (2025) iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors. *Cell reports. Medicine*, 6(7), 102195.

Chauveau C, et al. (2025) MEK inhibition prevents human skin graft rejection by promoting CD8+TCF1+ over CD8 effector T cells. *iScience*, 28(9), 113310.

Liu L, et al. (2025) TWEAK-Fn14 signaling protects mice from pulmonary fibrosis by inhibiting fibroblast activation and recruiting pro-regenerative macrophages. *Cell reports*, 44(2), 115220.

Gaspar M, et al. (2025) An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. *Journal for immunotherapy of cancer*, 13(8).

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. *Frontiers in immunology*, 16, 1609658.

Li Z, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. *Cell*, 187(3), 624.

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. *Cell stem cell*, 31(9), 1376.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Fiore G, et al. (2024) Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy. *Frontiers in immunology*, 15, 1433119.

Huang YH, et al. (2024) Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. *Cell reports. Medicine*, 5(2), 101416.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Li Z, et al. (2024) Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors. *STAR protocols*, 5(3), 103096.

Ming Z, et al. (2023) IFN- γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics. *The Journal of investigative dermatology*, 143(7), 1246.